Effects of polymorphisms of the SLCO2B1 transporter gene on the pharmacokinetics of montelukast in humans

Journal of Clinical Pharmacology

Volumn 53, Issue 11, 2013, Pages 1186-1193

  Kim, Kyoung Ah ^a   Lee, Hye Mi ^a   Joo, Hyun Jin ^a   Park, In Bae ^a   Park, Ji Young ^a  

^a College of Medicine   (South Korea)

Author keywords

Montelukast; OATP2B1; Pharmacogenetics; Pharmacokinetics; SLCO2B1

Indexed keywords

DRUG METABOLITE; MONTELUKAST; ORGANIC ANION TRANSPORTER B;

ADULT; AMINO ACID SUBSTITUTION; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; GENE; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PROMOTER REGION; PYROSEQUENCING; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; SLCO2B1 GENE; TIME TO MAXIMUM PLASMA CONCENTRATION; YOUNG ADULT;

MONTELUKAST; OATP2B1; PHARMACOGENETICS; PHARMACOKINETICS; SLCO2B1;

ACETATES; ADULT; ANTI-ASTHMATIC AGENTS; HUMANS; LEUKOTRIENE ANTAGONISTS; MALE; ORGANIC ANION TRANSPORTERS; POLYMORPHISM, SINGLE NUCLEOTIDE; QUINOLINES; YOUNG ADULT;

EID: 84892919369     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.144     Document Type: Article

References (23)

1. Drazen JM. Pharmacology of leukotriene receptor antagonists and 5lipoxygenase inhibitors in the management of asthma. Pharmacotherapy. 1997;17(1 Pt 2):22S-30S.
2. Hay DW. Pharmacology of leukotriene receptor antagonists. More than inhibitors of bronchoconstriction. Chest. 1997;111(2 Suppl): 35S-45S.
3. Knorr B, Matz J, Bernstein JA, et al. Montelukast for chronic asthma in 6 to 14yearold children: A randomized, doubleblind trial. Pediatric Montelukast Study Group. JAMA. 1998;279(15):1181- 1186.
4. Capra V, Rovati GE. Leukotriene modifiers in asthma management. IDrugs. 2004;7(7):659-666.
5. Bisgaard H. Leukotriene modifiers in pediatric asthma management. Pediatrics. 2001;107(2):381-390.
6. Chiba M, Xu X, Nishime JA, Balani SK, Lin JH. Hepatic microsomal metabolism of montelukast, a potent leukotriene D4 receptor antagonist, in humans. Drug Metab Dispos. 1997;25(9): 1022-1031.
7. Tamai I, Nezu J, Uchino H, et al. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000;273(1):251-260.
8. Nakanishi T, Tamai I. Genetic polymorphisms of OATP transporters and their impact on intestinal absorption and hepatic disposition of drugs. Drug Metab Pharmacokinet. 2012;27(1):106- 121.
9. Grube M, Kock K, Oswald S, et al. Organic anion transporting polypeptide 2B1 is a highaffinity transporter for atorvastatin and is expressed in the human heart. Clin Pharmacol Ther. 2006; 80(6): 607-620.
10. Tamai I. Oral drug delivery utilizing intestinal OATP transporters. Adv Drug Deliv Rev. 2012;64(6):508-514.
11. Mougey EB, Feng H, Castro M, Irvin CG, Lima JJ. Absorption of montelukast is transporter mediated: A common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics. 2009;19(2):129-138.
12. Mougey EB, Lang JE, Wen X, Lima JJ. Effect of citrus juice and SLCO2B1 genotype on the pharmacokinetics of montelukast. J Clin Pharmacol. 2011;51(5):751-760.
13. Tapaninen T, Karonen T, Backman JT, Neuvonen PJ, Niemi M. SLCO2B1 c.935G>A single nucleotide polymorphism has no effect on the pharmacokinetics of montelukast and aliskiren. Pharmacogenet Genomics. 2013;23(1):19-24.
14. Kim KA, Joo HJ, Lee HM, Park JY. SLCO2B1 genetic polymorphisms in a Korean population: Pyrosequencing analyses and comprehensive comparison with other populations. Mol Biol Rep. 2013;40(7):4211-4217.
15. Ieiri I, Doi Y, Maeda K, et al. Microdosing clinical study: Pharmacokinetic, pharmacogenomic (SLCO2B1), and interaction (grapefruit juice) profiles of celiprolol following the oral microdose and therapeutic dose. J Clin Pharmacol. 2012;52(7): 1078-1089.
16. Imanaga J, Kotegawa T, Imai H, et al. The effects of the SLCO2B1 c.1457C>T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans. Pharmacogenet Genomics. 2011;21(2):84-93.
17. Nozawa T, Nakajima M, Tamai I, et al. Genetic polymorphisms of human organic anion transporters OATPC (SLC21A6) and OATPB (SLC21A9): Allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther. 2002;302(2):804- 813.
18. Akamine Y, Miura M, Sunagawa S, et al. Influence of drugtransporter polymorphisms on the pharmacokinetics of fexofenadine enantiomers. Xenobiotica. 2010;40(11):782-789.
19. Ho RH, Leake BF, Kim RB, Wang Y. OATP2B1 allelic variants differentially transport rosuvastatin in vitro. Drug Metab Rev. 2006;38(Suppl 2):S240-S241.
20. Aoki M, Terada T, Ogasawara K, et al. Impact of regulatory polymorphisms in organic anion transporter genes in the human liver. Pharmacogenet Genomics. 2009;19(8):647-656.
21. Chu X, Philip G, Evers R, Comments on Mougey, et al. Absorption of montelukast is transporter mediated: A common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics. 2009;19:129-138.
22. Pharmacogenet Genomics. 2012; 22(4): 319-322.
23. Tapaninen T, Neuvonen PJ, Niemi M. Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren. Br J Clin Pharmacol. 2011;71(5):718-726.